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cular administration of adiponectin in mice decreased body
weight by stimulating energy expenditure, adiponectin may
also promote wasting.5 Interestingly, high, but not low,
molecular weight adiponectin has been associated with
increased energy expenditure in CKD.6 Because to date it is
unknown if dialysis alters the proportion of the different
adiponectin isoforms, we cannot speculate on the possibility
of a uremic accumulation of high molecular weight
adiponectin. In any case, in the context of CKD, elevated
adiponectin may be confounded by, or alternatively, act as an
inducer of protein-energy wasting. Thus, future epidemiolo-
gical studies should take into account this potentially
malevolent ‘Mr Hyde side’ of adiponectin.
1. Costacou T, Orchard TJ. Adiponectin: good, bad, or just plain ugly?.
Kidney Int 2008; 74: 549–551.
2. Yang WS, Lee WJ, Funahashi T et al. Weight reduction increases plasma
levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin
Endocrinol Metab 2001; 86: 3815–3819.
3. Kistorp C, Faber J, Galatius S et al. Plasma adiponectin, body mass index,
and mortality in patients with chronic heart failure. Circulation 2005; 112:
1756–1762.
4. Matsumoto M, Ishikawa S, Kajii E. Adiponectin and noncardiovascular
death: a nested case–control study. Metabolism 2008; 57: 811–818.
5. Qi Y, Takahashi N, Hileman SM et al. Adiponectin acts in the brain to
decrease body weight. Nat Med 2004; 10: 524–529.
6. Barazzoni R, Stulle M, Panzetta G et al. Plasma high- but not low-
molecular weight adiponectin is positively associated with resting energy
expenditure in male non-diabetic hemodialysis patients (Abstract). J Ren
Nutr 2008; 18: S36.
Juan J. Carrero1, Lovisa Brodin1, Bengt Lindholm2
and Peter Stenvinkel1
1Division of Renal Medicine, CLINTEC, Karolinska Institutet, Karolinska
University Hospital at Huddinge, Stockholm, Sweden and 2Baxter Novum,
CLINTEC, Karolinska Institutet, Karolinska University Hospital at Huddinge,
Stockholm, Sweden
Correspondence: Peter Stenvinkel, Department of Renal Medicine K56,
Karolinska Institutet, Karolinska University Hospital at Huddinge, 141 86
Stockholm, Sweden. E-mail: peter.stenvinkel@ki.se
Response to ‘Adiponectin in
chronic kidney disease: Dr Jekyll
and Mr Hyde’
Kidney International (2009) 75, 121; doi:10.1038/ki.2008.542
We thank Carrero et al.1 for their thoughtful comments
and for bringing up an important issue. Indeed, adipo-
nectin’s involvement in protein-energy wasting may be
both possible and perhaps a constituent of this ‘paradox’.
However, we failed to observe differences in body mass
index between those who progressed to renal function
decline (o30 ml/min per 1.73 m2) and those who did not
progress among the 108 participants of the Epidemiology
of Diabetes Complications Study with a diagnosis of type 1
diabetes and overt nephropathy at study entry. Thus, the
elevation in adiponectin concentration in progressors
throughout the 16-year follow-up period was not accom-
panied by differences in body mass index in this
population. It should be noted here that these data were
based on a small subsample of the Epidemiology of
Diabetes Complications cohort and need to be replicated
in larger samples. Nevertheless, they and Dr Carrero’s
observations add more complexity to an already intricate
issue, reminding us that there is probably quite a bit more
to be learned regarding this adipokine.
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